收藏切换
Efficacy and safety analysis of oral therapeutic drugs for hyperuricemia
收藏切换
Wen-yuan XIA, Xue-chen LI*, Fei YE*
Acta Pharmaceutica Sinica | 2026, 61(5) : 1450 - 1459
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(5): 1450-1459
• Reviews •
Efficacy and safety analysis of oral therapeutic drugs for hyperuricemia
Full
Wen-yuan XIA, Xue-chen LI*, Fei YE*
Affiliations
  • Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Published: 2026-05-12 doi: 10.16438/j.0513-4870.2025-1319
Outline
收藏切换

Hyperuricemia is a metabolic disease characterized by abnormally elevated level of serum uric acid, which is the key pathological basis of gout. Oral medications reduce blood uric acid level by inhibiting uric acid production and/or promoting uric acid excretion. Xanthine oxidoreductase is the rate-limiting enzyme for uric acid synthesis, by inhibiting its activity, the production of uric acid will be reduced. Urate transporter 1 (URAT1), one of the important proteins mediating uric acid reabsorption in kidney, is also a main target of anti-hyperuricemic drugs. By inhibiting URAT1 activity, the uric acid excretion will be promoted, thereby reducing the blood uric acid. At present, three xanthine oxidoreductase inhibitors and two urate transporter 1 inhibitors have been launched, and multiple compounds are currently in clinical trials. The physiological functions and metabolic pathways of uric acid, etiology of hyperuricemia and its therapeutic targets are introduced in this review. We analyze the efficacy and safety of oral therapeutic agents, to provide insights for the development of new drugs and the rational clinical use of medications in the treatment of hyperuricemia.

hyperuricemia  /  medication efficacy  /  medication safety  /  xanthine oxidoreductase inhibitor  /  urate transporter 1 inhibitor
夏闻远, 李雪晨, 叶菲. 高尿酸血症口服治疗药物的疗效及安全性分析. 药学学报, 2026 , 61 (5) : 1450 -1459 . DOI: 10.16438/j.0513-4870.2025-1319
Wen-yuan XIA, Xue-chen LI, Fei YE. Efficacy and safety analysis of oral therapeutic drugs for hyperuricemia[J]. Acta Pharmaceutica Sinica, 2026 , 61 (5) : 1450 -1459 . DOI: 10.16438/j.0513-4870.2025-1319
Year 2026 volume 61 Issue 5
391
192
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2025-1319
  • Receive Date:2025-11-07
  • Online Date:2026-09-21
  • Published:2026-05-12
Article Data
Affiliations
History
  • Received:2025-11-07
  • Revised:2026-01-26
Affiliations
    Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-1319
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT